Loading clinical trials...
Loading clinical trials...
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
The purpose of this extension study is to evaluate the safety, tolerability, and pharmacokinetics of repeat administrations of SRP-5051 (vesleteplirsen) in participants with Duchenne muscular dystrophy (DMD) who participated in studies of SRP-5051.
Age
4 - No limit years
Sex
MALE
Healthy Volunteers
No
Connecticut Children's Medical Center
Hartford, Connecticut, United States
NW FL Clinical Research Group, LLC
Gulf Breeze, Florida, United States
Center for Integrative Rare Disease Research (CIRDR)
Atlanta, Georgia, United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
Children's Medical Center Dallas
Dallas, Texas, United States
London Health Sciences Centre
London, Ontario, Canada
Start Date
December 19, 2018
Primary Completion Date
August 25, 2021
Completion Date
August 25, 2021
Last Updated
September 19, 2024
15
ACTUAL participants
SRP-5051
DRUG
Lead Sponsor
Sarepta Therapeutics, Inc.
NCT03992430
NCT05429372
NCT03963453
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions